Influenza Neuraminidase Virus-Like Particle-Based Nanocarriers as a New Platform for the Delivery of Small-Peptide Antigens

Journal article

Authors/Editors

Strategic Research Themes

Publication Details

Author list: Khanefard N.; Trianti I.; Akeprathumchai S.; Mekvichitsaeng P.; Roshorm Y.M.; Poomputsa K.

Publisher: Springer

Publication year: 2025

Journal: Molecular Biotechnology (1073-6085)

ISSN: 1073-6085

eISSN: 1559-0305

URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85219008220&doi=10.1007%2fs12033-025-01403-x&partnerID=40&md5=0de05092d7e8a2a2845a4c0768ea2da4

Languages: English-Great Britain (EN-GB)

View on publisher site

Abstract

A new and simple platform to produce a nanocarrier for small-peptide antigen delivery was developed. Virus-like particles (VLPs) were of interest due to their good cell-penetrating properties and ability to protect target molecules from degradation. In this study, the VLP that was entirely formed by influenza neuraminidase (NA), NA-VLPs, was employed. The platform construction includes the genetic engineering of target peptides into the NA structure immediately above its stalk, at the bottom of the NA head, by an overlap extension PCR. The resulting chimeric gene is next expressed in stably transformed insect cells. The recombinant NA protein produced by the insect cells is then naturally assembled into the NA-VLPs that display those peptides on their surfaces. For the platform demonstration, Angiotensin II (AngII) octapeptide hormones that raise blood pressure were chosen as a model peptide antigen. The NA-VLPs displaying AngII peptides were successfully produced by the stably transformed insect cells. The AngII octapeptides were successfully delivered by the NA-AngII VLPs as the anti-AngII antibodies were raised in hypertensive rats. The antibodies effectively neutralized the AngII peptide hormone in these rats, as demonstrated by the decrease in systolic blood pressure of the immunized rats. Thus, NA-VLP nanocarriers represent a promising platform for delivering small-peptide antigens to stimulate antibody production. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.

Keywords

No matching items found.